MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma

NCT00094653 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1783

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma
Metastases

Interventions

DRUG: MDX-010 (anti-CTLA4) monoclonal antibody
BIOLOGICAL: MDX-1379 (gp100) Melanoma Peptide Vaccine

Sponsor

Bristol-Myers Squibb